Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review
Sign Up to like & getrecommendations! Published in 2022 at "Osteoporosis International"
DOI: 10.1007/s00198-021-06268-9
Abstract: This paper systematically reviewed and assessed all retrievable pharmacoeconomic studies on denosumab for the treatment of osteoporosis. Denosumab was more cost-effective in patients with older age, prior fracture experience, lower BMD T-scores, and more risk… read more here.
Keywords: pharmacoeconomic studies; denosumab osteoporosis; cost; osteoporosis ... See more keywords
Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases
Sign Up to like & getrecommendations! Published in 2022 at "Internal Medicine"
DOI: 10.2169/internalmedicine.8560-21
Abstract: Objective Denosumab, an anti-RANKL monoclonal antibody, was reported to improve bone mineral density (BMD) and reduce fracture risk, offering favorable efficacy against postmenopausal osteoporosis. However, some patients have experienced a reduced BMD despite denosumab therapy.… read more here.
Keywords: disease patients; efficacy denosumab; rheumatic disease; serum levels ... See more keywords